{
 "PrintNo":"A7533","Session":2019,"Chamber":"ASSEMBLY","BillType":"Assembly","Published":"2019-05-09T09:20:06.022147Z",
 "Status":"IN_ASSEMBLY_COMM","Committee":"Health",
 "Milestones":[{"Type":"IN_ASSEMBLY_COMM","Date":"2020-01-08","Committee":"Health"}],
 "Actions":[
  {"Text":"REFERRED TO HEALTH","Date":"2019-05-09","Chamber":"ASSEMBLY"},
  {"Text":"REFERRED TO HEALTH","Date":"2020-01-08","Chamber":"ASSEMBLY"}
 ],
 "Sponsors":[{"ID":657,"Name":"Patricia Fahy","Short":"FAHY"}],
 "Title":"Relates to dihydropyrimidine dehydrogenase deficiency testing",
 "Summary":"Requires dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrmidine or other antimetabolite treatment; requires policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; provides for dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program.",
 "LawSection":"Public Health Law",
 "LawCode":"Add §2400-a, Pub Health L; amd §§3216, 3221 & 4303, Ins L; add §365-o, Soc Serv L",
 "ActClause":"AN ACT to amend the public health law, in relation to requiring dihydropyrimidine dehydrogenase deficiency testing for certain individuals with cancer; to amend the insurance law, in relation to requiring policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; and to amend the social services law, in relation to the provision of dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program",
 "SameAsPrintNo":"S984-2019","PreviousVersions":["A11279-2017"]
}